Doxorubicin
- Generic Name
- Doxorubicin
- Brand Names
- Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 23214-92-8
- Unique Ingredient Identifier
- 80168379AG
- Background
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...
- Indication
Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...
- Associated Conditions
- AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
- Associated Therapies
- -
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Tanja Andrea Gruber
- Target Recruit Count
- 22
- Registration Number
- NCT04996160
- Locations
- 🇺🇸
Lucile Packard Children's Hospital Stanford, Stanford, California, United States
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT04996004
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT04980222
- Locations
- 🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04978584
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- ADC Therapeutics S.A.
- Registration Number
- NCT04974996
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)
- Conditions
- Interventions
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 66
- Registration Number
- NCT04968106
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Curie, Paris, France
A Study of N9 Chemotherapy in Children With Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT04947501
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
- Conditions
- Interventions
- Biological: RituximabDrug: EtoposideBiological: CopanlisibDrug: CyclophosphamideDrug: DoxorubicinDrug: VincristineDrug: PrednisoneDiagnostic Test: ECHODiagnostic Test: EKGDiagnostic Test: MRI BrainDiagnostic Test: 18F-FDG - PETDiagnostic Test: CT ScanProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDiagnostic Test: Lumbar Puncture (LP)
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 8
- Registration Number
- NCT04933617
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2022-11-07
- Target Recruit Count
- 289
- Registration Number
- NCT04922567
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 80
- Registration Number
- NCT04914741
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.